Using FAPI PET/MRI to Evaluate Prostate Cancer

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT06675357
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Prostate Cancer Metastatic Disease
  • Prostate Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FAPI — RADIATION
    5 +/- 2 mCi of Ga-FAPI-46
  • Positron Emission Tomography (PET) — PROCEDURE
    Undergo PET scan
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI scan

Study Details

The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.

Key Dates

Start date
Feb 27, 2026
Status verified
Jun 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Fibroblast activation protein inhibitor (FAPI)
    FAPI radiotracer will be used during PET

Primary Outcome Measure

Performance of FAPI for lesion detection [ Time Frame: Duration of scan, up to 80 minutes ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of WisconsinMadisonWisconsin53705
Ali Pirasteh, MD (PRINCIPAL_INVESTIGATOR)
Joshua Lang, PhD (SUB_INVESTIGATOR)
Diego Hernando, PhD (SUB_INVESTIGATOR)
Steven Cho, MD, PhD (SUB_INVESTIGATOR)
Glenn Liu, MD (SUB_INVESTIGATOR)
Alan McMillan, PhD (SUB_INVESTIGATOR)

Find similar trials in Madison, WI

By research site
University of Wisconsin· Madison, WI

Related Studies